Clinical Trial Update: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating recombinant vaccinia virus in combination with cemiplimab for renal cell carcinoma; the study is active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Recombinant vaccinia virus (investigational) (null)

Snippet

Sponsor: SillaJen, Inc. | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING